Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with adv
Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes..
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.